Advisors Capital Management LLC increased its position in shares of Johnson & Johnson (NYSE:JNJ) by 8.8% during the second quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 109,299 shares of the company’s stock after buying an additional 8,799 shares during the quarter. Advisors Capital Management LLC’s holdings in Johnson & Johnson were worth $13,262,000 at the end of the most recent quarter.

A number of other hedge funds have also recently added to or reduced their stakes in the stock. Saybrook Capital NC raised its stake in shares of Johnson & Johnson by 10.5% in the second quarter. Saybrook Capital NC now owns 74,312 shares of the company’s stock valued at $9,017,000 after acquiring an additional 7,035 shares during the last quarter. Captrust Financial Advisors raised its stake in shares of Johnson & Johnson by 14.7% in the second quarter. Captrust Financial Advisors now owns 151,091 shares of the company’s stock valued at $18,333,000 after acquiring an additional 19,389 shares during the last quarter. Peak Capital Management LLC bought a new position in shares of Johnson & Johnson in the second quarter valued at approximately $207,000. Commonwealth Bank of Australia raised its stake in shares of Johnson & Johnson by 16.1% in the second quarter. Commonwealth Bank of Australia now owns 223,762 shares of the company’s stock valued at $27,060,000 after acquiring an additional 30,999 shares during the last quarter. Finally, Ropes Wealth Advisors LLC raised its stake in shares of Johnson & Johnson by 0.5% in the second quarter. Ropes Wealth Advisors LLC now owns 83,584 shares of the company’s stock valued at $10,142,000 after acquiring an additional 431 shares during the last quarter. 66.51% of the stock is currently owned by institutional investors and hedge funds.

Several research firms recently weighed in on JNJ. Zacks Investment Research cut shares of Johnson & Johnson from a “buy” rating to a “hold” rating in a research report on Tuesday, November 27th. Wells Fargo & Co restated an “outperform” rating and issued a $160.00 price objective (up previously from $155.00) on shares of Johnson & Johnson in a research report on Wednesday, October 17th. Credit Suisse Group boosted their price objective on shares of Johnson & Johnson from $149.00 to $152.00 and gave the stock an “outperform” rating in a research report on Wednesday, October 17th. Citigroup boosted their price objective on shares of Johnson & Johnson from $137.00 to $148.00 and gave the stock a “neutral” rating in a research report on Monday, October 22nd. Finally, Raymond James boosted their price objective on shares of Johnson & Johnson from $144.00 to $149.00 and gave the stock an “outperform” rating in a research report on Wednesday, October 17th. Two analysts have rated the stock with a sell rating, seven have assigned a hold rating and ten have assigned a buy rating to the company’s stock. The stock presently has a consensus rating of “Hold” and an average price target of $143.90.

In other Johnson & Johnson news, CAO Ronald A. Kapusta sold 8,441 shares of the company’s stock in a transaction on Thursday, November 8th. The shares were sold at an average price of $145.15, for a total transaction of $1,225,211.15. Following the completion of the sale, the chief accounting officer now owns 17,284 shares in the company, valued at approximately $2,508,772.60. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, insider Joaquin Duato sold 40,000 shares of the company’s stock in a transaction on Wednesday, November 7th. The shares were sold at an average price of $144.36, for a total transaction of $5,774,400.00. Following the sale, the insider now owns 112,848 shares of the company’s stock, valued at approximately $16,290,737.28. The disclosure for this sale can be found here. Insiders have sold a total of 510,544 shares of company stock valued at $74,414,877 in the last quarter. Corporate insiders own 0.22% of the company’s stock.

JNJ stock opened at $145.43 on Monday. The company has a debt-to-equity ratio of 0.46, a current ratio of 1.72 and a quick ratio of 1.40. Johnson & Johnson has a fifty-two week low of $118.62 and a fifty-two week high of $148.99. The company has a market capitalization of $390.17 billion, a P/E ratio of 19.92, a P/E/G ratio of 2.27 and a beta of 0.59.

Johnson & Johnson (NYSE:JNJ) last issued its earnings results on Tuesday, October 16th. The company reported $2.05 EPS for the quarter, beating the consensus estimate of $2.03 by $0.02. The company had revenue of $20.35 billion during the quarter, compared to analysts’ expectations of $20.05 billion. Johnson & Johnson had a net margin of 1.89% and a return on equity of 34.62%. The business’s revenue for the quarter was up 3.6% compared to the same quarter last year. During the same quarter in the previous year, the company posted $1.90 EPS. As a group, sell-side analysts forecast that Johnson & Johnson will post 8.16 EPS for the current fiscal year.

The firm also recently announced a quarterly dividend, which will be paid on Tuesday, December 11th. Shareholders of record on Tuesday, November 27th will be given a dividend of $0.90 per share. This represents a $3.60 annualized dividend and a dividend yield of 2.48%. The ex-dividend date is Monday, November 26th. Johnson & Johnson’s payout ratio is 49.32%.

COPYRIGHT VIOLATION NOTICE: “Advisors Capital Management LLC Purchases 8,799 Shares of Johnson & Johnson (JNJ)” was reported by Daily Political and is the sole property of of Daily Political. If you are reading this story on another website, it was illegally stolen and republished in violation of US and international trademark & copyright laws. The correct version of this story can be read at https://www.dailypolitical.com/2018/12/10/advisors-capital-management-llc-purchases-8799-shares-of-johnson-johnson-jnj.html.

About Johnson & Johnson

Johnson & Johnson is a holding company, which engages in the research and development, manufacture and sale of products in the health care field. It operates through the following segments: Consumer, Pharmaceutical, and Medical Devices. The Consumer segment includes products used in the baby care, oral care, beauty, over-the-counter pharmaceutical, women’s health, and wound care markets.

Featured Article: Cost of Debt

Institutional Ownership by Quarter for Johnson & Johnson (NYSE:JNJ)

Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.